ArticleHepatology international2021
Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients.
Article in Hepatology international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Convergent application of traditional Chinese medicine and gut microbiota in ameliorate of cirrhosis: a data mining and Mendelian randomization study.Frontiers in cellular and infection microbiology · 2023Pooled it
- Molecular Basis and Clinical Significance of the High-risk Phenotype of Hepatitis B Virus Genotype C.Journal of clinical and translational hepatology · 2026Review
- Research Communication: Changing Aetiology of Chronic Liver Diseases in East Asia Pacific and HCC Surveillance in Non-Cirrhotic Patients.Alimentary pharmacology & therapeutics · 2026Article
- SEROLOGICAL CLEARANCE OF HBSAG IN CHRONIC HEPATITIS B: EXPERIENCE IN A UNIVERSITY HOSPITAL.Arquivos de gastroenterologia · 2026Article
- Patient and public health perspectives to inform expansion of hepatitis B treatment guidelines.The lancet. Gastroenterology & hepatology · 2025Review
- Scientific and medical evidence informing expansion of hepatitis B treatment guidelines.The lancet. Gastroenterology & hepatology · 2025Review
- Prognostic nutritional index is a better inflammation based prognostic marker in elderly patients with hepatocellular carcinoma after surgery.Scientific reports · 2025Article
- Genetic evidence for the causal influence of inflammatory factors on intrahepatic cholangiocarcinoma risk.World journal of gastrointestinal oncology · 2025Article
- Necessity of antiviral treatment for patients with chronic hepatitis B in the grey zone based on liver pathology analysis.Annals of medicine · 2024Article
- Probability analysis of hepatocellular carcinoma in hepatitis patients in the gray zone.Frontiers in medicine · 2024Article
- Distinct on-treatment HCC risks associated with different decompensation events in HBV patients with cirrhosis.Hepatology international · 2023Article
- Global burden of hepatitis B virus: current status, missed opportunities and a call for action.Nature reviews. Gastroenterology & hepatology · 2023Review
- From Non-Alcoholic Fatty Liver Disease to Liver Cancer: Microbiota and Inflammation as Key Players.Pathogens (Basel, Switzerland) · 2023Review
- Review
- The Interaction between Flavonoids and Intestinal Microbes: A Review.Foods (Basel, Switzerland) · 2023Review
- Gaps in hepatocellular carcinoma surveillance among insured patients with hepatitis B infection without cirrhosis in the United States.Hepatology communications · 2022Article
- Sex-specific analysis of microRNA profiles in HBV-associated cirrhosis by small RNA-sequencing.Hepatology communications · 2022Article
- Interferon add-on therapy increased clinical cure significantly for interferon-experienced chronic hepatitis B patients with low HBsAg.Frontiers in immunology · 2022Article
- A CpG Methylation Signature as a Potential Marker for Early Diagnosis of Hepatocellular Carcinoma From HBV-Related Liver Disease Using Multiplex Bisulfite Sequencing.Frontiers in oncology · 2021Article
- Management of patients with CHB outside the guidelines: Insights from Egyptian cohort with long-term follow-up.Clinical liver diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
52 authors at 20 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIncreasing hepatitis-related mortality has reignited interest to fulfill the World Health Organization's goal of viral hepatitis elimination by 2030. However, economic barriers have enabled only 28% of countries to implement countermeasures. Given the high disease burden among Asians, we aimed to present age, sex, disease activity and treatment-specific annual progression rates among Asian chronic hepatitis B (CHB) patients to inform health economic modeling efforts and cost-effective public health interventions.
methodsWe analyzed 18,056 CHB patients from 36 centers across the U.S. and seven countries/regions of Asia Pacific (9530 treated; 8526 untreated). We used Kaplan-Meier methods to estimate annual incidence of cirrhosis and hepatocellular carcinoma (HCC). Active disease was defined by meeting the APASL treatment guideline criteria.
resultsOver a median follow-up of 8.55 years, there were 1178 incidences of cirrhosis and 1212 incidences of HCC (297 without cirrhosis, 915 with cirrhosis). Among the 8526 untreated patients (7977 inactive, 549 active), the annual cirrhosis and HCC incidence ranged from 0.26% to 1.30% and 0.04% to 3.80% in inactive patients, and 0.55 to 4.05% and 0.19 to 6.03% in active patients, respectively. Of the 9530 treated patients, the annual HCC rates ranged 0.03-1.57% among noncirrhotic males and 2.57-6.93% among cirrhotic males, with lower rates for females. Generally, transition rates increased with age, male sex, the presence of fibrosis/cirrhosis, and active disease and/or antiviral treatment.
conclusionUsing data from a large and diverse real-world cohort of Asian CHB patients, the study provided detailed annual transition rates to inform practice, research and public health planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.